Navigation Links
Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
Date:5/21/2008

ated with long-term survival in many patients, including four who survived for 11 to over 18 months. Mechanism-of-action of JX-594 was validated in patients by demonstration of tumor-specific replication and tissue destruction with JX- 594, in addition to high-level active expression of the GM-CSF protein in the blood of patients. These results led to the initiation of a Phase II liver cancer trial that is now open in the U.S., and will shortly begin enrolling patients at sites in South Korea and Canada, as well.

About JX-594

JX-594 is a cancer biotherapeutic, currently in Phase II trials, from a proprietary class of targeted and armed oncolytic poxviruses. Tumor destruction and safety was shown in patients with diverse cancer types in three Phase I trials; treated patients were end-stage and had no effective therapies available. JX-594 multiplies selectively within cancer cells, leading to their destruction. These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells both locally and in distant sites in the body. This cycle of JX-594 replication, cancer cell destruction, release and spread is then repeated. Normal cells are not affected by JX-594 resulting in safety and tolerability. The poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program against smallpox. This strain naturally targets cancer cells due to common genetic defects in cancer cells. JX-594 was engineered to enhance this natural safety and cancer-selectivity by deleting its thymidine kinase (TK) gene, thus making it dependent on the cellular TK expressed at persistently high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attack.
'/>"/>

SOURCE Jennerex
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
6. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
7. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
10. Promising Cystic Fibrosis Compound on Track for Development
11. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/bf3b6l/electrocardiogram ) has ... - Global Trends, Estimates and Forecasts, 2012-2018" report ... Global Electrocardiogram Devices (ECG) sector is ... North America accounts for nearly 36% ... Europe claims approximately 27% (2018). ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition of the ... 2012-2018"  report to their offering. Global Guidewires sector ... North America accounts for nearly ... Europe claims approximately 25% (2018). ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals Inc. ... that its Board of Directors has elected Mr. Daniel Kazado ... who continues as Chief Executive Officer of Immune. Mr. Kazado ... 2013. Immune,s new Chairman, Mr. Daniel Kazado ... shareholders and to continue to support the strategic vision of ...
Breaking Medicine Technology:Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... April 21 Strativa,Pharmaceuticals, the proprietary products ... PRX ) today announced that its development ... a Phase III,study of Loramyc(R) (miconazole Lauriad(R)) ... candidiasis (OPC)., Top line data show ...
... Nostrum, a privately-held,company based in Edison, ... completed its early, primate, proof-of-concept study for ... SMRX11. Nostrum,s,Symmetrix subsidiary, based in Singapore, is ... from the Institute of Microbial,Technology, Chandigarh, India, ...
Cached Medicine Technology:Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis 2Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis 3Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Wittenberg, MD, uses an,investor,s technology to yield the ... 6 When Scottsdale businessman,Warren Kaplan decided a ... had no,idea that an innovative medical product Possis ... gifted interventional radiologist - save his daughter,s life., ...
... Nov. 6 Repligen Corporation,(Nasdaq: RGEN ) ... Phase 2b,clinical trial to evaluate the use of ... bipolar depression. This Phase 2b study is a,multi-center, ... patients with bipolar depression will receive,either RG2417 or ...
... SALT LAKE CITY, Nov. 6 "In a remarkable ... history of cosmetics, women around the,country have been applying ... of fine lines, wrinkles and crows, feet." Five years ... a revolution in the cosmetic,industry: a little-known American stretch-mark ...
... 6 Performance Health Technologies,Inc. (PHT), a leader ... guide and monitor exercise and rehabilitation, announced,today that ... the September 5 edition of "60 Second Science," ... "Virtual Rehabilitation: Wireless Motion Sensor to Help,Treat That ...
... NEW YORK, Nov. 6 According to the ... The African,American community is one of the groups ... diagnosed. With November being National Diabetes Month,Black Expressions(R) ... that raise,awareness about diabetes and offer information about ...
... Salud to Use Pan-Enterprise Search Platform to,Identify ... and SAN FRANCISCO, November 6 /PRNewswire-FirstCall/,-- Autonomy ... global leader in,infrastructure software for the enterprise ... Spain,s most innovative health service,provider, has selected ...
Cached Medicine News:Health News:Innovative Deep Vein Thrombosis Treatment Yields Priceless Payoff 2Health News:Innovative Deep Vein Thrombosis Treatment Yields Priceless Payoff 3Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 2Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 3Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 4Health News:Happy Birthday, StriVectin! The Skin Cream that Revolutionized the Anti-Aging Market 2Health News:Happy Birthday, StriVectin! The Skin Cream that Revolutionized the Anti-Aging Market 3Health News:Performance Health Technologies Garners Additional Media Coverage, Including Scientific American's News Blog 2Health News:Performance Health Technologies Garners Additional Media Coverage, Including Scientific American's News Blog 3Health News:National Diabetes Month Book Suggestions From Black Expressions(R) Book Club 2Health News:Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare 2Health News:Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare 3Health News:Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare 4
... and model 1488 active-fixation leads are among ... the unsurpassed handling advantages, performance, and reliability ... active-fixation leads. Implantable with a 7 F ... Tendril SDX lead is designed to lower ...
... Tendril SDX model 1688 and model 1488 ... extendable/retractable pacing leads, offering the unsurpassed handling ... Jude Medical's line of active-fixation leads. Implantable ... body diameter of the Tendril SDX lead ...
... battery-backed up, microprocessor based, quality instrument that monitors ... and displays a chart on its large panel ... or zoomed into and out of, so that ... months can be seen at one time. ...
... Aegis CheckPoint is an automated, wireless, ... and alert system for refrigerator, freezer, ... chart recorders, data loggers and manual ... on an existing PC and comes ...
Medicine Products: